Liraglutide

Last Updated: August 2026

Liraglutide is an acylated GLP-1 receptor agonist that is ~97% homologous to native human GLP-1, engineered with a C16 fatty-acid chain (via a glutamic-acid spacer) so it self-associates and resists DPP-4 degradation, extending its half-life to about 13 hours for once-daily dosing.1 source It is FDA-approved as Victoza® (type 2 diabetes, and cardiovascular risk reduction) and Saxenda® (chronic weight management), developed by Novo Nordisk. In the research market it is sold for research use only and is not the approved pharmaceutical.

What is Liraglutide and why does the GLP-1 mechanism matter?

Liraglutide activates the GLP-1 receptor to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite — the core incretin mechanism that also drives weight loss. It is the once-daily predecessor to the once-weekly GLP-1 agonists like semaglutide, and a useful reference point for the whole incretin class. Evidence level: FDA-approved (human clinical pharmacology).

What does the clinical evidence show?

Liraglutide has an extensive human evidence base — it is approved across multiple large randomized programs for glycemic control, cardiovascular risk reduction (in T2D), and weight management (Saxenda at 3 mg). The anchor is the LEADER cardiovascular-outcomes trial (N Engl J Med 2016): 9,340 patients with type 2 diabetes at high cardiovascular risk, median follow-up 3.8 years — major adverse cardiovascular events occurred in 13.0% on liraglutide vs 14.9% on placebo (hazard ratio 0.87, 95% CI 0.78–0.97), with cardiovascular death also lower (4.7% vs 6.0%).1 source That result underpins Victoza's approved indication to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.1 source For weight, the 56-week SCALE Obesity and Prediabetes trial (N Engl J Med 2015) underpins Saxenda; in the label's pivotal 56-week study, liraglutide 3 mg produced a −7.4% mean weight change vs −3.0% on placebo, with 62.3% vs 34.4% of patients losing ≥5% — modest relative to newer agents, reflecting its earlier-generation profile.2 sources Evidence level: FDA-approved (human RCTs).

How does liraglutide compare with semaglutide, tirzepatide, and retatrutide?

Liraglutide is the once-daily, earlier-generation member of the incretin class, and its weight-loss effect is roughly half that of the newer weekly agents. Its distinctive assets are the LEADER cardiovascular-outcomes result and a 15-year approved safety record; the newer agents beat it decisively on weight. Figures below are each trial's own published result — different trials, durations, and populations, not head-to-head comparisons. Evidence level: FDA-approved (human RCTs); retatrutide Phase 2.

Browse the full weight-loss & metabolic peptide category.

What are the documented side effects of Liraglutide?

The most common effects are gastrointestinal (nausea, diarrhea, vomiting, constipation); documented serious risks include pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors (contraindicated in personal/family history of medullary thyroid carcinoma or MEN2).1 source Because it is approved, these are established from controlled data. Evidence level: FDA labeling.

What is the regulatory status, and how does research-market material differ?

Liraglutide is FDA-approved (and approved in the EU, UK, etc.), but products sold through research-chemical vendors are not the approved Victoza/Saxenda pharmaceutical and are marketed for research use only. Two 2024–2026 developments matter here. First, generic liraglutide reached the US market: the FDA approved the first generic of a once-daily GLP-1 injection (liraglutide 18 mg/3 mL, referencing Victoza) on December 23, 2024 — noting at the time that liraglutide was in shortage —1 source and a first generic referencing Saxenda (weight management) followed in August 2025.1 source Generic liraglutide is a prescription-pharmacy product, not a research chemical. Second, on April 30, 2026 the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances; the comment period closed June 29, 2026 and no final rule had issued as of August 2026.1 source That distinction drives the purity/provenance question. See the legal status guide.

Why does vendor verification matter, and how does Peptigrity verify?

Because research-market liraglutide is not the approved product, HPLC purity and mass-spec identity (expected MW ~3751 Da) are the objective checks that a vial contains the correct GLP-1 analog at the labeled amount. Peptigrity collects independent third-party Certificates of Analysis for liraglutide from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. The trust score weights lab purity and reviews equally (50/50). Compare any vendor claim against the independent liraglutide lab tests on file. See how to read lab results.

This section is for educational and informational purposes only and does not constitute medical advice. Research-grade liraglutide sold for laboratory use is not an FDA-approved product. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.